-
Jan 16, 2025 | 
nature.com | Farwa Ali |Michelle M. Mielke |Clifford R. Jack |David S. Knopman |Prashanthi Vemuri |Ronald Petersen | +1 more
AbstractDeclining gait performance is seen in aging individuals, due to neural and systemic factors. Plasma biomarkers provide an accessible way to assess evolving brain changes; non-specific neurodegeneration (NfL, GFAP) or evolving Alzheimer’s disease (Aβ 42/40 ratio, P-Tau181). In a population-based cohort of older adults, we evaluate the hypothesis that plasma biomarkers of neurodegeneration and Alzheimer’s Disease pathology are associated with worse gait performance.
-
Jan 13, 2025 | 
nature.com | Michael Fang |David S. Knopman |Keenan A. Walker |Rebecca Gottesman |Elizabeth Selvin
AbstractUnderstanding the lifetime risk of dementia can inform public health planning and improve patient engagement in prevention. Using data from a community-based, prospective cohort study (n = 15,043; 26.9% Black race, 55.1% women and 30.8% with at least one apolipoprotein E4 (APOE ε4) allele), we estimated the lifetime risk of dementia (from age 55 years to 95 years), with mortality treated as a competing event.
-
Jan 8, 2025 | 
alz-journals.onlinelibrary.wiley.com | Gil D. Rabinovici |Biomedical Imaging |David S. Knopman |Javier Arbizu
1 INTRODUCTION AND SCOPE Alzheimer's disease (AD) is defined neuropathologically by the deposition of extracellular plaques composed of aggregated forms of the amyloid-beta (Aβ) polypeptide and intraneuronal neurofibrillary tangles (NFTs) composed of aggregated hyperphosphorylated tau protein.1, 2 In the past 20 years, positron emission tomography (PET) radiotracers have been developed to image amyloid plaques and tau tangles in vivo.3-9 Currently, three fluorine-18-labeled amyloid...
-
Jan 7, 2025 | 
jnm.snmjournals.org | Gil D. Rabinovici |David S. Knopman |Javier Arbizu |Tammie L.S. Benzinger
Using the evidence summary, their clinical experience and expertise, and their knowledge of research outside of the scope of the evidence review, the workgroup used a modified Delphi approach to reach consensus on ratings for each of the clinical scenarios. This approach consisted of an online survey and 2 rounds of virtual scoring. When rating each scenario, workgroup members were asked to assess the benefits and risks to patients of using amyloid and tau PET imaging for the diagnosis of AD.
-
Oct 2, 2023 | 
n.neurology.org | David S. Knopman |Linda A. Hershey
REQUIREMENTSYou must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information. Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
-
Aug 10, 2023 | 
nature.com | Murray Grossman |Adam L Boxer |David S. Knopman |Henrik Zetterberg
AbstractFrontotemporal lobar degeneration (FTLD) is one of the most common causes of early-onset dementia and presents with early social–emotional–behavioural and/or language changes that can be accompanied by a pyramidal or extrapyramidal motor disorder. About 20–25% of individuals with FTLD are estimated to carry a mutation associated with a specific FTLD pathology.
-
Jun 9, 2023 | 
n.neurology.org | David S. Knopman |Linda A. Hershey
REQUIREMENTSYou must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information. Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
-
May 29, 2023 | 
nature.com | Emily S. Lundt |Christopher Schwarz |Matthew L. Senjem |Robert Reid |David S. Knopman |Prashanthi Vemuri | +3 more
In this work, we used an AFT model to study the association of individual adjustments in timing of AD and CVD biomarker progression. These findings are important in informing the proposed relationships between AD (defined as an accumulation of pathological aggregated amyloid and tau proteins) and small vessel cerebrovascular disease. The individual adjustments of AD biomarkers (amyloid and tau PET) and established CVD biomarkers (WMH and FA GCC) showed weak to no association.
-
Mar 21, 2023 | 00088-5&sz=64)
cell.com | David S. Knopman
Main textInvestigators from Eisai reported a successful phase 3 trial of lecanemab, an antiamyloid monoclonal antibody that targets soluble amyloid-β protofibrils, in individuals with early symptomatic Alzheimer disease (AD). 1van Dyck C.H. Swanson C.J. Aisen P. Bateman R.J. Chen C. Gee M. Kanekiyo M. Li D. Reyderman L. Cohen S. et al. Lecanemab in early Alzheimer's disease.
-
Feb 18, 2023 | 
alz-journals.onlinelibrary.wiley.com | Jason SMith |Jason Smith |A. Richey Sharrett |Rebecca Gottesman |David S. Knopman
2.6 Sensitivity analysis We repeated analyses, including potential mediators in Cox models. Second, given some evidence for the non-proportionality of hazards for some covariates, we also repeated the primary analysis using weighted Cox regression models to estimate the average HRs.28 Third, we imputed missing hypertension and covariate data (Figure ) using multiple imputation by chained equations, with 20 sets of imputations,29 using the mice package in R.
